Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01834911 · ClinicalTrials.gov registry record · Phase 4
Effect of Tetrabenazine on Stroop Interference in HD
A Phase 4 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT01834911: Completed Phase 4 study, sponsored by New York Medical College.
NCT01834911 is a Phase 4 study that has completed, run by New York Medical College. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01834911, a Phase 4 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.
Primary Outcome
Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement. Patients are analyzed according to Stroop test using Golden's Interference score (theoretical min -50, theoretical max about 98) cal
Interventions
- DRUG Tetrabenazine withdrawal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-03 |
| Est. Completion | 2018-01-01 |
| Phase | Phase 4 |
What the finished NCT01834911 record still lists
NCT01834911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Tetrabenazine withdrawal is the first listed.
NCT01834911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01834911 about?
NCT01834911 is a clinical study titled "Effect of Tetrabenazine on Stroop Interference in HD". Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a...
What is the current status of trial NCT01834911?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2013-03. Estimated completion is 2018-01-01.
What interventions are being tested in trial NCT01834911?
The interventions under investigation include: Tetrabenazine withdrawal (DRUG).
Who is sponsoring clinical trial NCT01834911?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01834911's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia